id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-5267-0007,FDA,FDA-2019-E-5267,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-12-18T05:00:00Z,2024,12,2024-12-18T05:00:00Z,,2024-12-18T19:20:40Z,,0,0,090000648687bf71
FDA-2019-E-5267-0006,FDA,FDA-2019-E-5267,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2024-01-19T05:00:00Z,2024,1,2024-01-19T05:00:00Z,,2024-01-19T13:06:02Z,,0,0,09000064863a7cd7
FDA-2019-E-5267-0005,FDA,FDA-2019-E-5267,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-17T05:00:00Z,2024,1,2024-01-17T05:00:00Z,,2024-01-17T19:20:22Z,,0,0,090000648639022c
FDA-2019-E-5267-0004,FDA,FDA-2019-E-5267,Determination of Regulatory Review Period for Purposes of Patent Extension; Nuzyra Tablets (New Drug Application 209816),Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T14:12:23Z,2023-26989,0,0,090000648631653b
FDA-2019-E-5267-0003,FDA,FDA-2019-E-5267,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-12-23T05:00:00Z,2019,12,2019-12-23T05:00:00Z,,2019-12-23T19:27:13Z,,0,0,090000648424b03b
FDA-2019-E-5267-0002,FDA,FDA-2019-E-5267,"Patent Term Extension Application from Paratek Pharmaceuticals, Inc",Other,Application,2019-11-07T05:00:00Z,2019,11,2019-11-07T05:00:00Z,,2019-11-07T16:46:27Z,,0,0,090000648412935d
FDA-2019-E-5267-0001,FDA,FDA-2019-E-5267,Letter from U S Patent and Trademark Office,Other,Letter(s),2019-11-07T05:00:00Z,2019,11,2019-11-07T05:00:00Z,,2019-11-07T16:42:33Z,,0,0,090000648412935b